Repligen Corp (RGEN) operating KPIs
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30122% above fair value
$176.94−11.70 (-6.20%)
Close on Oct 30, 2026Market cap $9.99BP/E –Yield –
KPIs
Operating metrics that drive Repligen's business
Coming soon
This tab will track the numbers specific to Repligen's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.